BD
MCID: BHC003
MIFTS: 70

Behcet Syndrome (BD)

Categories: Bone diseases, Cardiovascular diseases, Eye diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Behcet Syndrome

MalaCards integrated aliases for Behcet Syndrome:

Name: Behcet Syndrome 57 12 73 20 43 44 37 70
Behcet's Syndrome 12 20 43 29 42 17
Behcet Disease 57 43 58 36 54 6
Behcet's Disease 12 20 53 15
Behçet Disease 20 43 32
Adamantiades-Behcet Disease 12 43
Triple Symptom Complex 12 43
Bd 57 20
Behcet Triple Symptom Complex 43
Old Silk Route Disease 43
Malignant Aphthosis 43
Behcet Disease; Bd 57
Behçet's Syndrome 20
Behet's Syndrome 12
Behçet's Disease 20
Syndrome, Behcet 39
Behçet Syndrome 20
Bd Syndrome 20

Characteristics:

Orphanet epidemiological data:

58
behcet disease
Inheritance: Multigenic/multifactorial; Prevalence: 1-5/10000 (Japan),>1/1000 (Turkey); Age of onset: Adolescent,Adult,Childhood; Age of death: adult;

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
familial cases reported, but probably not mendelian


HPO:

31
behcet syndrome:
Inheritance autosomal recessive inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases
Rare circulatory system diseases
Rare renal diseases
Rare systemic and rhumatological diseases
Rare skin diseases


Summaries for Behcet Syndrome

MedlinePlus Genetics : 43 Behçet disease is an inflammatory condition that affects many parts of the body. The health problems associated with Behçet disease result from widespread inflammation of blood vessels (vasculitis). This inflammation most commonly affects small blood vessels in the mouth, genitals, skin, and eyes.Painful mouth sores called aphthous ulcers are usually the first sign of Behçet disease. These sores can occur on the lips, tongue, inside the cheeks, the roof of the mouth, the throat, and the tonsils. The ulcers look like common canker sores, and they typically heal within one to two weeks. About 75 percent of all people with Behçet disease develop similar ulcers on the genitals. These ulcers occur most frequently on the scrotum in men and on the labia in women.Behçet disease can also cause painful bumps and sores on the skin. Most affected individuals develop pus-filled bumps that resemble acne. These bumps can occur anywhere on the body. Some affected people also have red, tender nodules called erythema nodosum. These nodules usually develop on the legs but can also occur on the arms, face, and neck.An inflammation of the eye called uveitis is found in more than half of people with Behçet disease. Eye problems are more common in younger people with the disease and affect men more often than women. Uveitis can result in blurry vision and an extreme sensitivity to light (photophobia). Rarely, inflammation can also cause eye pain and redness. If untreated, the eye problems associated with Behçet disease can lead to blindness.Joint involvement is also common in Behçet disease. Often this affects one joint at a time, with each affected joint becoming swollen and painful and then getting better.Less commonly, Behçet disease can affect the brain and spinal cord (central nervous system), gastrointestinal tract, large blood vessels, heart, lungs, and kidneys. Central nervous system abnormalities can lead to headaches, confusion, personality changes, memory loss, impaired speech, and problems with balance and movement. Involvement of the gastrointestinal tract can lead to a hole in the wall of the intestine (intestinal perforation), which can cause serious infection and may be life-threatening.The signs and symptoms of Behçet disease usually begin in a person's twenties or thirties, although they can appear at any age. Some affected people have relatively mild symptoms that are limited to sores in the mouth and on the genitals. Others have more severe symptoms affecting various parts of the body, including the eyes and the vital organs. The features of Behçet disease typically come and go over a period of months or years. In most affected individuals, the health problems associated with this disorder improve with age.

MalaCards based summary : Behcet Syndrome, also known as behcet's syndrome, is related to spondylitis and spondyloarthropathy 1, and has symptoms including angina pectoris, chest pain and pruritus. An important gene associated with Behcet Syndrome is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Fluocinolone Acetonide and Pharmaceutical Solutions have been mentioned in the context of this disorder. Affiliated tissues include eye, spinal cord and heart, and related phenotypes are nausea and vomiting and arthritis

Disease Ontology : 12 A vasculitis that is characterized by an autoimmune mediated inflammation of the blood vessels throughout the body leading to ulcerations on the mouth and sometimes the genitals, notorious for causing hypopyon uveitis.

GARD : 20 Behcet disease leads to swelling of the blood vessels and affects multiple organs throughout the body. Symptoms generally begin when individuals are in their 20s or 30s, but may occur at any age.Symptoms may include ulcers affecting the mouth and genitals, various skin lesions, and swelling of the membranes affecting the eyes. In some people, symptoms include arthritis (swollen, painful, stiff joints), skin problems, and inflammation of the digestive tract, brain, and spinal cord. Symptoms of Behcet disease may be active and then become inactive, but they never completely go away. In some cases, Behcet disease may lead to vision loss and neurological problems. The exact cause of Behcet disease is unknown, but it is thought to be due to a combination of genetic, immune, and environmental factors. Diagnosis is based on the symptoms and clinical examination. Diagnostic guidelines have been published. Treatment is focused on managing the symptoms and includes steroids and drugs that suppress the immune system.

MedlinePlus : 42 Behcet's syndrome is a disease that involves vasculitis, which is inflammation of the blood vessels. It causes problems in many parts of the body. The most common symptoms are Sores in the mouth Sores on the sex organs Other skin sores Swelling of parts of the eye Pain, swelling and stiffness of the joints More serious problems can include meningitis, blood clots, inflammation of the digestive system and blindness. Doctors aren't sure what causes Behcet's. It is rare in the United States, but is common in the Middle East and Asia. It mainly affects people in their 20s and 30s. Diagnosing Behcet's can take a long time, because symptoms may come and go, and it may take months or even years to have all of the symptoms. There is no cure. Treatment focuses on reducing pain and preventing serious problems. Most people can control symptoms with treatment. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

NINDS : 53 Behcet's disease is a rare, chronic inflammatory disorder. The cause of Behcet's disease is unknown, but current research suggests that both genetic and  environmental factors play a role.  Behcet's disease generally begins when individuals are in their 20s or 30s, although it can happen at any age. It tends to occur more often in men than in women. Symptoms of Behcet's disease include recurrent ulcers in the mouth (resembling canker sores) and on the genitals, and eye inflammation. The disorder may also cause various types of skin lesions, arthritis, bowel inflammation, meningitis (inflammation of the membranes of the brain and spinal cord), and cranial nerve palsies. Behcet's is a multi-system disease; it may involve all organs and affect the central nervous system, causing memory loss and impaired speech, balance, and movement. The effects of the disease may include blindness, stroke, swelling of the spinal cord, and intestinal complications. The disease is common in the Middle East, particularly in Turkey, and in Far Eastern nations such as Japan and Korean, but is less common in the United States.

KEGG : 36 Behcet disease is a multisystemic inflammatory disease characterized by relapsing episodes of oral aphthous ulcers, genital ulcers, other skin lesions, and uveitis. It can also involve visceral organs such as the gastrointestinal tract, pulmonary, musculoskeletal, cardiovascular and neurological systems. This disease is more common in countries along the ancient Silk Road, including Asia, Middle East, and Mediterranean. Although the etiology is still unknown, this disease is believed to be triggered by environmental factors such as microbial agents in individuals with a particular genetic background. The positive association of HLA-B51 was identified more than four decades ago, and has been confirmed in multiple populations. Recent genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet disease.

Wikipedia : 73 Behçet's disease (BD) is a type of inflammatory disorder which affects multiple parts of the body. The... more...

More information from OMIM: 109650

Related Diseases for Behcet Syndrome

Diseases related to Behcet Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1069)
# Related Disease Score Top Affiliating Genes
1 spondylitis 31.6 TNF NOD2 IL23R IL10 HLA-B ERAP1
2 spondyloarthropathy 1 31.6 TNFRSF1A TNF TLR4 NOD2 IL23R HLA-B
3 erythema nodosum 31.4 TNF NOD2 IL10
4 vogt-koyanagi-harada disease 31.4 IL23R IL10 HLA-B FAS
5 exanthem 31.3 TNF MEFV IL10
6 pyoderma 31.3 TNF PSTPIP1 NOD2 MEFV
7 pyoderma gangrenosum 31.3 TNF PSTPIP1 NOD2 MEFV
8 iridocyclitis 31.3 UBAC2 TNF TLR4 RBP3 IL10 HLA-B
9 systemic lupus erythematosus 31.2 TNFRSF1A TNF TLR4 STAT4 NOD2 IL10
10 intestinal perforation 31.2 TNF TLR4 NOD2
11 lymphadenitis 31.2 TNF TLR4 NOD2 IL10 FAS
12 arthritis 31.2 TNFRSF1A TNF TLR4 STAT4 PSTPIP1 NOD2
13 pericarditis 31.2 TNFRSF1A TNF MEFV
14 crohn's disease 31.1 TNFRSF1A TNF TLR4 STAT4 NOD2 MEFV
15 autoimmune disease 31.1 TNFRSF1A TNF STAT4 RBP3 IL23R IL10
16 familial mediterranean fever 31.1 TNFRSF1A TNF TLR4 PSTPIP1 NOD2 MEFV
17 panuveitis 31.1 TNF RBP3 NOD2 IL23R IL10 HLA-B
18 iritis 31.1 TNF RBP3 NOD2 IL10 HLA-B ERAP1
19 hypopyon 31.1 UBAC2 TNF RBP3 KLRC4 IL10 HLA-B
20 inflammatory bowel disease 31.1 TNFRSF1A TNF TLR4 STAT4 PSTPIP1 NOD2
21 aphthous stomatitis 31.1 TNF TLR4 MEFV IL10 HLA-B CCR1
22 urethritis 31.1 TNF TLR4 IL10
23 colitis 31.1 TNF TLR4 NOD2 IL23R IL10
24 psoriasis 31.1 TNFRSF1A TNF NOD2 IL23R IL10 HLA-B
25 tonsillitis 31.1 TNF TLR4 IL10
26 autoimmune uveitis 31.1 TNF STAT4 RBP3 IL10
27 peritonitis 31.1 TNF TLR4 MEFV IL10
28 brucellosis 31.1 TNF TLR4 MEFV IL10
29 myelitis 31.1 TNFRSF1A TNF IL10
30 vasculitis 31.0 TNF MEFV HLA-B ADA2
31 rheumatoid arthritis 31.0 TNFRSF1A TNF TLR4 STAT4 IL23R IL10
32 psoriatic arthritis 31.0 TNFRSF1A TNF NOD2 IL23R IL10 HLA-B
33 juvenile rheumatoid arthritis 31.0 TNFRSF1A TNF STAT4 IL10
34 palindromic rheumatism 31.0 TNFRSF1A TNF MEFV
35 disease by infectious agent 31.0 TNFRSF1A TNF TLR4 NOD2 IL10
36 chorioretinitis 31.0 TNF RBP3 NOD2 IL10
37 pleurisy 31.0 TNF TLR4 MEFV ADA2
38 spondylarthropathy 30.9 TNF TLR4 HLA-B
39 lupus erythematosus 30.9 TNF STAT4 IL10 C4A
40 myocarditis 30.9 TNF TLR4 IL10 HLA-B
41 thrombocytopenia 30.9 TNFRSF1A TNF TLR4 IL10 HLA-B FAS
42 sclerosing cholangitis 30.9 TNF TLR4 NOD2 IL10 HLA-B
43 cholangitis 30.9 TNF TLR4 NOD2 IL10 HLA-B
44 celiac disease 1 30.9 TNF TLR4 STAT4 NOD2 IL23R IL10
45 uveitis 30.9 TNFRSF1A TNF RBP3 NOD2 IL10 HLA-B
46 monocytic leukemia 30.9 TNFRSF1A TNF TLR4 FAS
47 bronchopneumonia 30.8 TNF TLR4 IL10
48 bacterial meningitis 30.8 TNF TLR4 IL10
49 purpura 30.8 TNF MEFV IL10
50 proteasome-associated autoinflammatory syndrome 1 30.8 TNF TLR4 MEFV IL10

Graphical network of the top 20 diseases related to Behcet Syndrome:



Diseases related to Behcet Syndrome

Symptoms & Phenotypes for Behcet Syndrome

Human phenotypes related to Behcet Syndrome:

58 31 (show top 50) (show all 81)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 31 hallmark (90%) Very frequent (99-80%) HP:0002017
2 arthritis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001369
3 photophobia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000613
4 fatigue 58 31 hallmark (90%) Very frequent (99-80%) HP:0012378
5 fever 58 31 hallmark (90%) Very frequent (99-80%) HP:0001945
6 subcutaneous nodule 58 31 hallmark (90%) Very frequent (99-80%) HP:0001482
7 myalgia 58 31 hallmark (90%) Very frequent (99-80%) HP:0003326
8 migraine 58 31 hallmark (90%) Very frequent (99-80%) HP:0002076
9 meningitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0001287
10 vasculitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002633
11 papule 58 31 hallmark (90%) Very frequent (99-80%) HP:0200034
12 orchitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0100796
13 oral ulcer 58 31 hallmark (90%) Very frequent (99-80%) HP:0000155
14 recurrent aphthous stomatitis 58 31 hallmark (90%) Very frequent (99-80%) HP:0011107
15 gait disturbance 58 31 frequent (33%) Frequent (79-30%) HP:0001288
16 acne 58 31 frequent (33%) Frequent (79-30%) HP:0001061
17 venous thrombosis 58 31 frequent (33%) Frequent (79-30%) HP:0004936
18 abdominal pain 58 31 frequent (33%) Frequent (79-30%) HP:0002027
19 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
20 gastrointestinal hemorrhage 58 31 frequent (33%) Frequent (79-30%) HP:0002239
21 abnormal blistering of the skin 58 31 frequent (33%) Frequent (79-30%) HP:0008066
22 immunologic hypersensitivity 58 31 frequent (33%) Frequent (79-30%) HP:0100326
23 hemiparesis 58 31 frequent (33%) Frequent (79-30%) HP:0001269
24 confusion 58 31 frequent (33%) Frequent (79-30%) HP:0001289
25 hyperreflexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001347
26 abnormal pyramidal sign 58 31 occasional (7.5%) Occasional (29-5%) HP:0007256
27 ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001251
28 developmental regression 58 31 occasional (7.5%) Occasional (29-5%) HP:0002376
29 encephalitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002383
30 cataract 58 31 occasional (7.5%) Occasional (29-5%) HP:0000518
31 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
32 increased intracranial pressure 58 31 occasional (7.5%) Occasional (29-5%) HP:0002516
33 avascular necrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0010885
34 malabsorption 58 31 occasional (7.5%) Occasional (29-5%) HP:0002024
35 blindness 58 31 occasional (7.5%) Occasional (29-5%) HP:0000618
36 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
37 retinopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0000488
38 cranial nerve paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006824
39 myocardial infarction 58 31 occasional (7.5%) Occasional (29-5%) HP:0001658
40 irritability 58 31 occasional (7.5%) Occasional (29-5%) HP:0000737
41 abnormal myocardium morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0001637
42 mitral regurgitation 58 31 occasional (7.5%) Occasional (29-5%) HP:0001653
43 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
44 vertigo 58 31 occasional (7.5%) Occasional (29-5%) HP:0002321
45 glomerulopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0100820
46 hemoptysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002105
47 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
48 cerebral ischemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002637
49 pericarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001701
50 endocarditis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100584

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Joints:
arthritis

Skin:
raynaud phenomenon
superficial thrombophlebitis
hyperirritability
erythema nodosum-like eruptions
pustular skin lesions

G U:
epididymitis
genital ulcerations

Neuro:
brainstem syndrome
meningoencephalomyelitic syndrome
organic confusional state
schizoaffective disorder

Eyes:
hypopyon
uveitis
iridocyclitis
iritis
choreoretinitis

Hair:
alopecia areata

Mouth:
mouth ulcerations

Clinical features from OMIM®:

109650 (Updated 20-May-2021)

UMLS symptoms related to Behcet Syndrome:


angina pectoris; chest pain; pruritus; edema; snoring; halitosis; exanthema; oral manifestations

GenomeRNAi Phenotypes related to Behcet Syndrome according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.99 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.99 CCR1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.99 CCR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-106 9.99 ADA2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.99 ADA2 C4A
6 Increased shRNA abundance (Z-score > 2) GR00366-A-111 9.99 ADA2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.99 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.99 HLA-B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.99 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.99 TLR4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-134 9.99 ADA2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.99 IL10
13 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.99 C4A IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-18 9.99 ADA2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-180 9.99 CCR1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.99 ADA2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.99 IL10
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.99 NOD2 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.99 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.99 TLR4
21 Increased shRNA abundance (Z-score > 2) GR00366-A-33 9.99 CCR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.99 NOD2 CCR1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.99 C4A
24 Increased shRNA abundance (Z-score > 2) GR00366-A-48 9.99 ADA2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.99 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.99 IL10
27 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.99 CCR1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.99 C4A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.99 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.99 IL10
31 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.99 IL10 TLR4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.99 HLA-B
33 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.99 C4A
34 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.99 ADA2
35 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.99 IL10
36 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.99 IL10
37 Increased shRNA abundance (Z-score > 2) GR00366-A-97 9.99 ADA2

MGI Mouse Phenotypes related to Behcet Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 CCR1 ERAP1 FAS IL10 IL12A IL23R
2 digestive/alimentary MP:0005381 9.86 CCR1 FAS IL10 IL23R NOD2 TLR4
3 immune system MP:0005387 9.77 CCR1 ERAP1 FAS IL10 IL12A IL23R
4 neoplasm MP:0002006 9.17 FAS IL10 IL12A IL23R TLR4 TNF

Drugs & Therapeutics for Behcet Syndrome

Drugs for Behcet Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4 67-73-2 6215
2 Pharmaceutical Solutions Phase 4
3
Adalimumab Approved, Experimental Phase 3 331731-18-1 16219006
4
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
6
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
7
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
8
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
9
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
10
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
11
Infliximab Approved Phase 3 170277-31-3
12
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
13
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
14 Antirheumatic Agents Phase 3
15 Anti-Infective Agents Phase 3
16 Antiviral Agents Phase 3
17 interferons Phase 3
18 Interferon-alpha Phase 3
19 Methylprednisolone Acetate Phase 3
20 Immunoglobulins Phase 3
21 Antibodies, Monoclonal Phase 3
22 Antibodies Phase 3
23 Antifungal Agents Phase 3
24 Cyclosporins Phase 3
25 Interferon alpha-2 Phase 3
26 Gastrointestinal Agents Phase 3
27 Dermatologic Agents Phase 3
28 Anti-Inflammatory Agents Phase 3
29 Anti-Inflammatory Agents, Non-Steroidal Phase 3
30 Analgesics Phase 3
31 Analgesics, Non-Narcotic Phase 3
32
Ustekinumab Approved, Investigational Phase 2 815610-63-0
33
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
34
rituximab Approved Phase 2 174722-31-7 10201696
35
Azathioprine Approved Phase 2 446-86-6 2265
36
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
37
Colchicine Approved Phase 2 64-86-8 6167 2833
38
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
39
Ethanol Approved Phase 2 64-17-5 702
40
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
41
Naltrexone Approved, Investigational, Vet_approved Phase 2 16590-41-3 5360515
42
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
43
Daclizumab Investigational, Withdrawn Phase 2 152923-56-3
44 Interleukin-12 Phase 2
45 Interleukin 1 Receptor Antagonist Protein Phase 1, Phase 2
46 Phosphodiesterase 4 Inhibitors Phase 2
47 Hemay005 Phase 2
48 Interleukin-2 Phase 2
49 Antimitotic Agents Phase 2
50 Tubulin Modulators Phase 2

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 A Multi-Center, Prospective Single Arm Study to Assess the Efficacy and Safety of RETISERT (Intravitreal Flucinolone Acetonide 0.59mg) in Patients With Refractory Ocular Behcet's Disease Unknown status NCT00720928 Phase 4 flucinolone acetonide
2 The Efficacy of Intravenous Pulses of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease, a Double Blind Pilot Study Unknown status NCT01306955 Phase 4 methylorednisolone
3 Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation Completed NCT03133767 Phase 4 Lactated Ringer Solution;Normal Saline 0.9% Infusion Solution Bag
4 A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease Completed NCT02307513 Phase 3 Apremilast;Placebo
5 To Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Patients With Behcet's Disease ( BD ) With Special Lesions After the Administration of TA-650 Completed NCT01532570 Phase 3 TA-650
6 A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease Completed NCT01243671 Phase 3
7 Randomized Prospective Comparative Study of Interferon α2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis Completed NCT03209219 Phase 3 Interferon Alfa-2A;Cyclosporine Pill
8 An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease Completed NCT02505568 Phase 3 Infliximab
9 Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB) Completed NCT00167583 Phase 3 Cyclosporin A;Interferon-alpha2a
10 A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
11 Efficacy of Humira in Behcet Patients With Arthritis Completed NCT01497717 Phase 3 Adalimumab (Humira)
12 Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease Not yet recruiting NCT03371095 Phase 3 Infliximab;Cyclophosphamide
13 A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN) Not yet recruiting NCT04528082 Phase 3 Apremilast;Placebo
14 A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis Terminated NCT01965145 Phase 3 Gevokizumab;Placebo
15 A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis Terminated NCT02258867 Phase 3 Placebo;Gevokizumab
16 A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Unknown status NCT02648581 Phase 2 Subcutaneous Ustekinumab
17 An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease Unknown status NCT03522662 Phase 2 GSK1070806
18 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
19 An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behçet's Disease Patients With Neurologic or Vascular Involvement Completed NCT02756650 Phase 2 Canakinumab
20 A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Active-Treatment Extension to Evaluate the Efficacy and Safety of Apremilast(CC-10004) in the Treatment of Behçet Disease Completed NCT00866359 Phase 2 Apremilast (CC-10004);Placebo
21 Phase II Study, Evaluation of Low Dose Natural Human Interferon Alpha Administered by the Oral Mucosal Route in the Treatment of Behçet's Disease Completed NCT00483184 Phase 2
22 Effect of Rituximab in the Treatment of Resistant Ocular Inflammatory Lesions of Behcet's Disease (Pilot Study) Completed NCT00664599 Phase 2 Rituximab;Cytotoxic Combination
23 A Double Blind Cross Over Clinical Trial to Determine Colchicine Efficacy in Behcet's Disease Completed NCT00700297 Phase 2 Colchicine;Placebo
24 A Study to Investigate the Safety and Efficacy of HAT to Treat the Ocular Complications Related to Behcet's Disease Completed NCT00001865 Phase 2 Daclizumab
25 A Pilot Study of Anakinra in Behcet's Disease (BD) Completed NCT01441076 Phase 1, Phase 2 Anakinra
26 Clinical Protocol for Administration of Topical Pentoxifylline Gel on Behcet's Disease Oral Ulcers Recruiting NCT03888846 Phase 2 Pentoxifylline;Colchicine
27 Efficacy and Safety of Golimumab in the Treatment of Refractory Uveitis in Patients With Behcet's Disease Recruiting NCT04218565 Phase 2
28 A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease Recruiting NCT04609397 Phase 2 Hemay005;Hemay005
29 Low-dose IL-2 Treatment on Behcet's Disease Recruiting NCT04065672 Phase 2 Low-dose IL-2
30 Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach Active, not recruiting NCT01988506 Phase 2 Interleukin 2
31 Impact of Colchicine and Low-dose Naltrexone on COVID-19 Disease Progression and Clinical Course in Hospitalized Patients Enrolling by invitation NCT04756128 Phase 2 Colchicine 0.6 mg;Naltrexone
32 Clinical Protocol to Evaluate Use of Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers Not yet recruiting NCT04186559 Phase 2 Topical Pentoxifylline Gel (Vehicle +PTX);Topical Placebo Gel (Vehicle)
33 Efficacy and Safety of Tocilizumab in the Treatment of Refractory Uveitis in Patients With Behcet's Disease Terminated NCT03554161 Phase 2
34 Tocilizumab for the Treatment of Behcet's Syndrome Terminated NCT01693653 Phase 2 Tocilizumab
35 A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome (FCAS) / Muckle-Wells Syndrome (MWS) and Behcet's Disease (BD) Withdrawn NCT01211977 Phase 1, Phase 2 XOMA 052
36 Phase 1 Study of Bone Marrow - Derived Stem Cell in the Treatment of Ocular Lesions of Behcet's Disease Terminated NCT00550498 Phase 1
37 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
38 Serum (PLR), (LMR), (MPV) and (NLR) in Behcet Disease and Their Correlation With Disease Activity Unknown status NCT03747354
39 Inactivity Behavior and Exercise Bariers in Patients With Behçet Disease Unknown status NCT03837236
40 Etanercept: Single Blind Control Study in Ocular Manifestations of Behcet's Disease Unknown status NCT00931957 Etanercept, Methotrexate, Prednisolone
41 Development and Preliminary Validation of the Behçet's Disease Overall Damage Index Unknown status NCT03803462
42 Active Control,Randomized,Double- Blinded Clinical Trial of BD Unknown status NCT03771768 Triamcinolone Acetonide
43 Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses Unknown status NCT01952275
44 Evaluation of Fibromyalgia With Disease Activity and Clinical Findings in Women With Behçet's Disease in Province Bursa Completed NCT03543709
45 Possible Role of Regulatory B Cells in Behçet's Disease: Special Interest in Cardiovascular System Completed NCT04376411
46 The Role of Rosuvastatin on Vascular Involvement in Behçet's Disease Completed NCT04328064 Rosuvastatin calcium 40mg;Placebo oral tablet
47 A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients Completed NCT02687828
48 Comparison of Psychological Symptoms in Patients With Behcet's Disease and Control Patients by Symptom Check List 90-Revised (SCL-90-R) Completed NCT00699985
49 Frequency of Fibromyalgia in Behcet Disease in Province Bursa Completed NCT03514056
50 The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease Completed NCT01720628

Search NIH Clinical Center for Behcet Syndrome

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Thalidomide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Behcet Syndrome cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Behcet Syndrome:
Bone marrow-derived stem cells for treatment of ocular lesions Behcet's disease
Embryonic/Adult Cultured Cells Related to Behcet Syndrome:
Bone marrow-derived stem cells PMIDs: 23773637 21199472

Cochrane evidence based reviews: behcet syndrome

Genetic Tests for Behcet Syndrome

Genetic tests related to Behcet Syndrome:

# Genetic test Affiliating Genes
1 Behcet's Syndrome 29

Anatomical Context for Behcet Syndrome

MalaCards organs/tissues related to Behcet Syndrome:

40
Eye, Spinal Cord, Heart, Bone Marrow, Tongue, Bone, Skin

Publications for Behcet Syndrome

Articles related to Behcet Syndrome:

(show top 50) (show all 700)
# Title Authors PMID Year
1
Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease. 54 57
9037047 1997
2
A family study of Behcet's syndrome. 57 61
718279 1978
3
Behcet's syndrome with neurological manifestations in two sisters. 57 61
4296824 1968
4
Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility. 57
28166214 2017
5
Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. 57
23396137 2013
6
Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. 57
23291587 2013
7
Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. 57
20622878 2010
8
Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. 57
20622879 2010
9
Proteomic surveillance of autoimmunity in Behcet's disease with uveitis: selenium binding protein is a novel autoantigen in Behcet's disease. 57
17343851 2007
10
Comparison of patients with Behçet's disease in the 1980s and 1990s. 57
15051217 2004
11
Identification of an autosomal recessive mode of inheritance in paediatric Behçet's families by segregation analysis. 57
12955762 2003
12
Conjunctival ulcers in Behçet's disease. 57
12799237 2003
13
Serum leptin concentration is increased in patients with Behçet's syndrome and is correlated with disease activity. 57
12174107 2002
14
Localization of the pathogenic gene of Behçet's disease by microsatellite analysis of three different populations. 57
11053265 2000
15
Familial aggregation in Behçet's disease: high frequency in siblings and parents of pediatric probands. 57
10393610 1999
16
Genetic analysis of families of patients with Behçet's syndrome: data incompatible with autosomal recessive inheritance. 57
3707215 1986
17
Familial cases of Behcet's disease. 57
4063168 1985
18
Close association of HLA-Bw51 with Behçet's disease. 57
6956266 1982
19
Familial Behçet's syndrome. 57
1009010 1976
20
Behçet's syndrome with arthritis. 57
5777255 1969
21
Familial recurrent orogenital ulceration. 57
13823878 1960
22
Antineutrophil Cytoplasmic Antibody Positivity Is Associated with Vascular Involvement in Behçet's Disease. 42
33527794 2021
23
The Impact of the 'Mis-Peptidome' on HLA Class I-Mediated Diseases: Contribution of ERAP1 and ERAP2 and Effects on the Immune Response. 42
33348540 2020
24
One year in review 2020: Behçet's syndrome. 42
33331271 2020
25
Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. 61 54
15823500 2005
26
[Concentration of procalcitonin and C-reactive protein in serum and erythrocyte sedimentation rate in active autoimmune diseases in children]. 54 61
14648981 2003
27
A human T-cell receptor recognizes 'O'-linked sugars from the hinge region of human IgA1 and IgD. 54 61
7821975 1994
28
Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases. 61
33482337 2021
29
Pattern of Uveitis in Iran: A Systematic Review. 61
33520132 2021
30
Cluster analysis of phenotypes of patients with Behçet's syndrome: a large cohort study from a referral center in China. 61
33514418 2021
31
Acute coronary syndrome in Behcet's syndrome: A systematic review. 61
32910756 2021
32
[Progress in interferon: A treatment of Behcet syndrome]. 61
33331331 2020
33
[Clinical analysis of golimumab in the treatment of severe/refractory cardiovascular involvement in Behcet syndrome]. 61
33331313 2020
34
[Co-existence of Guillain-Barré syndrome and Behcet syndrome: A case report]. 61
33331329 2020
35
[Current research on cytokine gene single nucleotide polymorphisms of Behcet's syndrome]. 61
33152845 2020
36
Acute Myocardial Infarction as the Initial Presentation of Behcet's Syndrome. 61
33376707 2020
37
Headache in Behçet's Disease. 61
32671593 2020
38
Management of Behcet's syndrome. 61
32348509 2020
39
Sexual dysfunction in Behçet's syndrome. 61
31595309 2020
40
[Clinical characteristics analysis of 1 808 rheumatism in-patients with oral candidiasis]. 61
31874483 2019
41
A Study to Assess The Efficacy of Local Application of Oral Probiotic in Treating Recurrent Aphthous Ulcer and Oral Candidiasis. 61
31741944 2019
42
Synbiotic Supplementation May Relieve Anterior Uveitis, an Ocular Manifestation in Behcet's Syndrome. 61
31000688 2019
43
HLAs in Autoimmune Diseases: Dependable Diagnostic Biomarkers? 61
30644346 2019
44
[Pseudo-tumor form of neuro-Behçet disease: case study and literature review]. 61
31692738 2019
45
An Unusual Cause of Fever. 61
31313562 2018
46
Penile pyoderma gangrenousm treated with cyclosporine: Case report. 61
30317330 2018
47
Behcet's Syndrome: Fear Not the Unknown. 61
30236452 2018
48
Concurrent presence of buccal mucosal and ophthalmologic lesions in Behcet's syndrome. 61
30510645 2018
49
Surgical treatment of intestinal perforation in Behçet Syndrome: an unusual presentation. 61
30574248 2018
50
Is Warfarin Indicated in Behcet's Syndrome Associated with Thrombosis? Reflections on Treatment and Death of a Patient. 61
29271390 2018

Variations for Behcet Syndrome

ClinVar genetic disease variations for Behcet Syndrome:

6 (show all 20)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IL18R1 NM_003855.5(IL18R1):c.59-1038C>A SNV association 916547 rs4851569 GRCh37: 2:102983247-102983247
GRCh38: 2:102366787-102366787
2 IL18R1 NM_003855.5(IL18R1):c.-29+1269C>T SNV association 916546 rs12999364 GRCh37: 2:102974129-102974129
GRCh38: 2:102357669-102357669
3 IL18R1 NM_003855.5(IL18R1):c.-29+2476T>G SNV association 916545 rs12987977 GRCh37: 2:102975336-102975336
GRCh38: 2:102358876-102358876
4 MEFV NM_000243.2(MEFV):c.332G>A (p.Gly111Glu) SNV Pathogenic 430715 rs751454741 GRCh37: 16:3304736-3304736
GRCh38: 16:3254736-3254736
5 TNFRSF1A NM_001065.3(TNFRSF1A):c.596T>C (p.Ile199Thr) SNV Pathogenic 234423 rs104895247 GRCh37: 12:6440048-6440048
GRCh38: 12:6330882-6330882
6 ADA2 NM_001282225.2(ADA2):c.1045G>A (p.Val349Ile) SNV Pathogenic 430693 rs74317375 GRCh37: 22:17669265-17669265
GRCh38: 22:17188375-17188375
7 TNFRSF1A NM_001065.4(TNFRSF1A):c.935G>A (p.Arg312Lys) SNV Pathogenic 378735 rs200900510 GRCh37: 12:6439066-6439066
GRCh38: 12:6329900-6329900
8 PSTPIP1 NM_003978.5(PSTPIP1):c.203C>T (p.Thr68Met) SNV Pathogenic 317171 rs201872851 GRCh37: 15:77310863-77310863
GRCh38: 15:77018522-77018522
9 MEFV NM_000243.2(MEFV):c.1099C>G (p.Leu367Val) SNV Pathogenic 375253 rs1057519328 GRCh37: 16:3299592-3299592
GRCh38: 16:3249592-3249592
10 ADA2 NM_001282225.2(ADA2):c.740C>T (p.Ala247Val) SNV Pathogenic 375251 rs750868279 GRCh37: 22:17684466-17684466
GRCh38: 22:17203576-17203576
11 MEFV NM_000243.2(MEFV):c.1211A>G (p.His404Arg) SNV Pathogenic 375252 rs755659290 GRCh37: 16:3299480-3299480
GRCh38: 16:3249480-3249480
12 ADA2 NM_001282225.2(ADA2):c.145C>T (p.Arg49Trp) SNV Pathogenic 375246 rs199614299 GRCh37: 22:17690423-17690423
GRCh38: 22:17209533-17209533
13 ADA2 NM_001282225.2(ADA2):c.927G>A (p.Met309Ile) SNV Pathogenic 375247 rs146597836 GRCh37: 22:17670877-17670877
GRCh38: 22:17189987-17189987
14 PSTPIP1 NM_003978.5(PSTPIP1):c.364G>A (p.Val122Ile) SNV Pathogenic 280941 rs886041107 GRCh37: 15:77320202-77320202
GRCh38: 15:77027861-77027861
15 PSTPIP1 NM_003978.5(PSTPIP1):c.865G>C (p.Asp289His) SNV Pathogenic 280942 rs774164456 GRCh37: 15:77325229-77325229
GRCh38: 15:77032888-77032888
16 NOD2 NM_001370466.1(NOD2):c.964C>T (p.Leu322Phe) SNV Pathogenic 268134 rs752615209 GRCh37: 16:50744867-50744867
GRCh38: 16:50710956-50710956
17 NOD2 NM_022162.2(NOD2):c.2197G>T (p.Val733Leu) SNV Pathogenic 267319 rs746055479 GRCh37: 16:50746019-50746019
GRCh38: 16:50712108-50712108
18 TNFRSF1A NM_001065.3(TNFRSF1A):c.463C>T (p.His155Tyr) SNV Pathogenic 267318 rs886039866 GRCh37: 12:6442542-6442542
GRCh38: 12:6333376-6333376
19 NOD2 NM_022162.2(NOD2):c.2446G>A SNV Pathogenic 267317 rs886040969 GRCh37: 16:50746268-50746268
GRCh38: 16:50712357-50712357
20 NOD2 NM_022162.2(NOD2):c.241C>G (p.Leu81Val) SNV Pathogenic 267320 rs34936594 GRCh37: 16:50733566-50733566
GRCh38: 16:50699655-50699655

Copy number variations for Behcet Syndrome from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 241985 8 6835170 6856724 Copy number DEFA1 Behcet''s disease

Expression for Behcet Syndrome

Search GEO for disease gene expression data for Behcet Syndrome.

Pathways for Behcet Syndrome

Pathways related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 TNFRSF1A TNF TLR4 PSTPIP1 NOD2 MEFV
2
Show member pathways
13.34 TNFRSF1A TNF TLR4 STAT4 IL23R IL12A
3
Show member pathways
13.31 TNFRSF1A TNF NOD2 IL23R IL12A IL10
4
Show member pathways
13.27 TNFRSF1A TNF IL23R IL12A IL10 FAS
5
Show member pathways
13.17 TNFRSF1A TNF TLR4 STAT4 IL12A IL10
6
Show member pathways
12.92 TNFRSF1A TNF TLR4 HLA-B FAS CCR1
7
Show member pathways
12.78 TNFRSF1A TNF TLR4 IL12A HLA-B FAS
8 12.77 TNFRSF1A TNF IL12A HLA-B FAS
9
Show member pathways
12.76 TNF KLRC4 IL12A IL10 HLA-B FAS
10
Show member pathways
12.58 TNF TLR4 PSTPIP1 IL10 FAS
11
Show member pathways
12.55 TNFRSF1A TNF TLR4 IL12A FAS
12 12.53 TNFRSF1A TNF STAT4 IL10 FAS
13
Show member pathways
12.45 TNF TLR4 STAT4 NOD2 IL23R IL12A
14
Show member pathways
12.38 STAT4 IL23R IL12A IL10
15
Show member pathways
12.3 TNFRSF1A TNF IL10 CCR1
16
Show member pathways
12.2 TNFRSF1A TNF TLR4 IL12A IL10
17 12.17 TNF TLR4 PSTPIP1 NOD2 MEFV
18
Show member pathways
12.12 TNFRSF1A TNF TLR4 STAT4 FAS
19 12.05 TNF TLR4 MEFV IL10
20 12.05 TNFRSF1A TNF TLR4 NOD2 IL12A IL10
21 11.94 TNF IL23R IL12A IL10
22 11.93 TNFRSF1A TNF NOD2 FAS
23 11.88 TNF TLR4 IL12A IL10
24
Show member pathways
11.82 TLR4 STAT4 IL23R
25
Show member pathways
11.77 TNFRSF1A TNF FAS
26 11.75 TNF IL23R IL12A IL10
27 11.72 TNF IL12A IL10
28 11.66 TNF TLR4 IL10
29 11.59 TNF TLR4 IL12A
30 11.56 TNFRSF1A TNF TLR4
31
Show member pathways
11.54 TNF TLR4 STAT4 IL12A IL10
32 11.53 TNFRSF1A TNF FAS
33 11.5 TNF TLR4 IL12A
34 11.46 TNF TLR4 IL12A IL10
35 11.45 TNFRSF1A TNF FAS
36 11.43 TNF TLR4 IL12A IL10 C4A
37 11.33 TNF TLR4 IL10
38 11.27 TNF IL12A IL10 FAS
39 11.1 TNFRSF1A TNF NOD2
40 11.04 TNFRSF1A TNF IL12A IL10 CCR1
41
Show member pathways
10.58 TNFRSF1A TNF IL12A IL10 FAS

GO Terms for Behcet Syndrome

Cellular components related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 TNFRSF1A TNF RBP3 IL12A IL10 ERAP1
2 extracellular region GO:0005576 9.81 TNFRSF1A TNF RBP3 IL12A IL10 FAS
3 external side of plasma membrane GO:0009897 9.35 TNF TLR4 IL23R FAS CCR1
4 cell surface GO:0009986 9.1 TNFRSF1A TNF TLR4 NOD2 HLA-B FAS

Biological processes related to Behcet Syndrome according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.21 TNFRSF1A TLR4 STAT4 PSTPIP1 IL12A IL10
2 innate immune response GO:0045087 9.98 TLR4 PSTPIP1 NOD2 MEFV IL23R HLA-B
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 TNF TLR4 NOD2 CCR1
4 defense response to bacterium GO:0042742 9.95 TNFRSF1A TNF TLR4 NOD2 IL10
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.93 TNFRSF1A TNF TLR4 NOD2
6 cellular response to lipopolysaccharide GO:0071222 9.91 TNF TLR4 NOD2 IL10
7 positive regulation of inflammatory response GO:0050729 9.88 TNFRSF1A TNF TLR4
8 regulation of inflammatory response GO:0050727 9.88 TNF TLR4 NOD2
9 positive regulation of interleukin-6 production GO:0032755 9.88 TNF TLR4 NOD2
10 positive regulation of JNK cascade GO:0046330 9.87 TNF TLR4 NOD2
11 cellular response to mechanical stimulus GO:0071260 9.86 TNFRSF1A TLR4 FAS
12 immune system process GO:0002376 9.86 TLR4 PSTPIP1 NOD2 MEFV IL23R HLA-B
13 negative regulation of tumor necrosis factor production GO:0032720 9.85 TLR4 NOD2 IL10
14 negative regulation of interleukin-6 production GO:0032715 9.85 TNF TLR4 IL10
15 apoptotic signaling pathway GO:0097190 9.85 TNF TLR4 FAS
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 TNF TLR4 NOD2
17 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.81 TNFRSF1A TNF TLR4
18 positive regulation of interleukin-8 production GO:0032757 9.81 TNF TLR4 NOD2
19 positive regulation of interleukin-1 beta production GO:0032731 9.8 TNF TLR4 NOD2
20 response to lipopolysaccharide GO:0032496 9.8 TLR4 NOD2 IL23R IL12A IL10
21 interleukin-12-mediated signaling pathway GO:0035722 9.76 STAT4 IL12A IL10
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 TNFRSF1A TNF IL23R IL12A
23 extrinsic apoptotic signaling pathway GO:0097191 9.75 TNF IL12A FAS
24 negative regulation of interferon-gamma production GO:0032689 9.74 TLR4 NOD2 IL10
25 positive regulation of interleukin-12 production GO:0032735 9.73 TLR4 NOD2 IL23R
26 defense response GO:0006952 9.72 TNFRSF1A TNF STAT4 NOD2 HLA-B
27 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.71 TNF TLR4 NOD2
28 positive regulation of ceramide biosynthetic process GO:2000304 9.7 TNFRSF1A TNF
29 detection of bacterium GO:0016045 9.7 NOD2 HLA-B
30 positive regulation of T cell mediated cytotoxicity GO:0001916 9.7 IL23R IL12A HLA-B
31 immune response GO:0006955 9.7 TNF TLR4 IL12A IL10 HLA-B FAS
32 interleukin-35-mediated signaling pathway GO:0070757 9.69 STAT4 IL12A
33 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 TLR4 IL10
34 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.68 TNF TLR4
35 regulation of establishment of endothelial barrier GO:1903140 9.68 TNFRSF1A TNF
36 interleukin-23-mediated signaling pathway GO:0038155 9.67 STAT4 IL23R
37 positive regulation of osteoclast differentiation GO:0045672 9.67 TNF IL23R CCR1
38 positive regulation of interferon-gamma production GO:0032729 9.67 TNF TLR4 IL23R IL12A
39 necroptotic signaling pathway GO:0097527 9.65 TNF FAS
40 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
41 death-inducing signaling complex assembly GO:0071550 9.65 TNFRSF1A TNF
42 negative regulation of interleukin-12 production GO:0032695 9.65 NOD2 MEFV IL10
43 positive regulation of lymphocyte proliferation GO:0050671 9.64 TLR4 IL12A
44 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.62 TNF NOD2
45 negative regulation of cytokine production involved in immune response GO:0002719 9.61 TNF IL10
46 positive regulation of NK T cell activation GO:0051135 9.6 IL23R IL12A
47 negative regulation of interleukin-18 production GO:0032701 9.59 NOD2 IL10
48 cytokine-mediated signaling pathway GO:0019221 9.5 TNFRSF1A TNF STAT4 IL23R IL12A IL10
49 inflammatory response GO:0006954 9.23 TNFRSF1A TNF TLR4 PSTPIP1 MEFV IL23R

Molecular functions related to Behcet Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor-activated receptor activity GO:0005031 8.96 TNFRSF1A FAS
2 interleukin-12 receptor binding GO:0005143 8.62 IL23R IL12A

Sources for Behcet Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....